Initiator Pharma A/S - Asset Resilience Ratio
Initiator Pharma A/S (INIT) has an Asset Resilience Ratio of 0.67% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2023)
This chart shows how Initiator Pharma A/S's Asset Resilience Ratio has changed over time. Check Initiator Pharma A/S strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Initiator Pharma A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Initiator Pharma A/S stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr200.00K | 0.67% |
| Total Liquid Assets | Skr200.00K | 0.67% |
Asset Resilience Insights
- Limited Liquidity: Initiator Pharma A/S maintains only 0.67% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Initiator Pharma A/S Industry Peers by Asset Resilience Ratio
Compare Initiator Pharma A/S's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX |
Biotechnology | 46.79% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 63.47% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Initiator Pharma A/S (2023–2023)
The table below shows the annual Asset Resilience Ratio data for Initiator Pharma A/S.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.67% | Skr200.00K ≈ $21.52K |
Skr29.79 Million ≈ $3.21 Million |
-- |
About Initiator Pharma A/S
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to t… Read more